通过向海外甩卖，“中国药茅”似乎找到了长久困扰自己的业绩修复之道。来源 | 巨潮WAVE恒瑞医药又收获了一份看起来非常漂亮的三季报。前三季度公司实现收入合计达201.89 亿元，同比增长18.67%；度归母净利润合计46.20 亿元，同比增长32.98%，扣非净利润合计46.16 亿元，同比增长37.38%。数字光鲜亮丽。但如果从单季度数据来看，就会发现不一样的另一面。三季度，恒瑞医药实现营业收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.